Drug protection concerns the European Union

The commercialization of drugs is a topic that still raises questions among the Europeans in the framework of the trade agreement Ecuador seeks to sign with that block. This issue was negotiated at the intellectual property board, which was one of the last to close during the round of negotiations in July 2014. The issue of protection of test data was permanently the stone in the shoe during the process.

Behind every drug there is a formula, which has been tested prior to its commercialization. The information obtained in these tests ensure their effectiveness and safety. “A drug can be commercialized in the market only if it has test data,” explains Alfredo Corral, an expert in intellectual property law. The legal expert noted that the test data protect creators, because when a new product (medicine or agrochemical) is developed, any manufacturer will be able, for a certain time, to rely on this information to develop a generic drug. (I)

Source: http://www.elcomercio.com/actualidad/proteccion-farmacos-codigoingenios-comercio-unioneuropea.html